首页 > 最新文献

Human Antibodies最新文献

英文 中文
Radiomics, aptamers and nanobodies: New insights in cancer diagnostics and imaging. 放射组学,适体体和纳米体:癌症诊断和成像的新见解。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200436
Abdullah O Alamoudi

At present, cancer is a major health issue and the second leading cause of mortality worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy and developing methods for disease prevention. Diagnosis of cancers at an early stage can promote timely medical intervention and effective treatment and will result in inhibiting tumor growth and development. Several advances have been made in the diagnostics and imagining technologies for early tumor detection and deciding an effective therapy these include radiomics, nanobodies, and aptamers. Here in this review, we summarize the main applications of radiomics, aptamers, and the use of nanobody-based probes for molecular imaging applications in diagnosis, treatment planning, and evaluations in the field of oncology to develop quantitative and personalized medicine. The preclinical data reported to date are quite promising, and it is predicted that nanobody-based molecular imaging agents will play an important role in the diagnosis and management of different cancer types in near future.

目前,癌症是一个主要的健康问题,也是全世界第二大死亡原因。研究人员一直在努力研究改进的治疗方法和早期检测方法,这对提高治疗效果和开发疾病预防方法都至关重要。癌症的早期诊断可以促进及时的医疗干预和有效的治疗,并将导致抑制肿瘤的生长和发展。在早期肿瘤检测和确定有效治疗的诊断和成像技术方面取得了一些进展,包括放射组学、纳米体和适体体。本文综述了放射组学、适体体和纳米探针在肿瘤诊断、治疗计划和评估方面的主要应用,以发展定量和个性化医疗。目前所报道的临床前数据都很有前景,预计在不久的将来,基于纳米体的分子显像剂将在不同类型癌症的诊断和治疗中发挥重要作用。
{"title":"Radiomics, aptamers and nanobodies: New insights in cancer diagnostics and imaging.","authors":"Abdullah O Alamoudi","doi":"10.3233/HAB-200436","DOIUrl":"https://doi.org/10.3233/HAB-200436","url":null,"abstract":"<p><p>At present, cancer is a major health issue and the second leading cause of mortality worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy and developing methods for disease prevention. Diagnosis of cancers at an early stage can promote timely medical intervention and effective treatment and will result in inhibiting tumor growth and development. Several advances have been made in the diagnostics and imagining technologies for early tumor detection and deciding an effective therapy these include radiomics, nanobodies, and aptamers. Here in this review, we summarize the main applications of radiomics, aptamers, and the use of nanobody-based probes for molecular imaging applications in diagnosis, treatment planning, and evaluations in the field of oncology to develop quantitative and personalized medicine. The preclinical data reported to date are quite promising, and it is predicted that nanobody-based molecular imaging agents will play an important role in the diagnosis and management of different cancer types in near future.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200436","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25346130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Prevalence of HLA DQ 2, 8 in children with celiac disease. 乳糜泻患儿HLA dq2,8的患病率
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200437
Seyed Mohsen Dehghani, Naqi Dara, Behrooz Gharesifar, Iraj Shahramian, Fatemeh Dalili, Morteza Salarzaei

Objective: Celiac disease is a chronic disease that affect small bowel by making its villi become atrophic. Various environmental and genetic factors have been identify as inducing factors for celiac disease. Most of the patients has one of the HLA DQ forms. Although the prevalence of these genes are variable in different areas of the world, we do not have a comprehensive information about this issue in our region. Thus the aim of present study is to investigate the prevalence of HLA DQ typing of patients who visited Emam Reza Gastroenterology clinic of Shiraz(IRAN).

Methods: In this case-control study all under 18 years old children who were diagnosed with celiac disease and have visited Emam Reza gastroenterology clinic were investigated. The diagnosis of celiac disease was made by history, physical exam, serologic test, and histopathology of duodenal biopsy. Blood sample was taken and HLA typing performed using PCR method at Motahari clinic cytology laboratory. Also those people who neither them self nor their first degree relatives were not case of celiac disease and underwent HLA typing for other reason were identified as control group. The statistical analysis was done using SPSS 18 software. The p value < 0.05 was identified as statistically significant.

Results: A total of 139 patients with celiac disease and 146 normal children were studied. The mean age of the patient with celiac disease were 9.1 years old with standard deviation of 3.4 years old. 64% of the celiac patients were girls and 36% were boys. While this proportion was 54.4% for boy and 48.6% for girls in control group. The most common HLA in celiac patients group were HLA DQ2 and 8 but the most common ones in control group were HLA DQ 8 and 5. Failure to Thrive were the most common signs of the celiac patients with a prevalence of 60 children. Total IgA titer were normal in 98.6% of the patients and TTG IgA titer were positive in 93.5% of the patients. The most common co existing disease with the celiac disease were diabetes with a prevalence of 30 children (66.7%).

Conclusion: present study reveals that the prevalence of the HLA DQ2 and 8 among patients with celiac disease is 72.6% and 53% in our normal population.

目的:乳糜泻是一种通过使小肠绒毛萎缩而影响小肠的慢性疾病。各种环境和遗传因素已被确定为乳糜泻的诱发因素。大多数患者有一种HLA DQ型。虽然这些基因的流行率在世界不同地区是不同的,但我们没有关于本地区这一问题的全面信息。因此,本研究的目的是调查到设拉子(伊朗)伊玛目礼萨胃肠病学诊所就诊的患者HLA - DQ分型的流行情况。方法:在本病例对照研究中,调查了所有18岁以下就诊于Emam Reza胃肠病学诊所的诊断为乳糜泻的儿童。乳糜泻的诊断是通过病史、体格检查、血清学检查和十二指肠活检的组织病理学来确定的。在Motahari临床细胞学实验室采集血样,采用PCR法进行HLA分型。同时,那些既不是自身也不是直系亲属没有乳糜泻但因其他原因进行HLA分型的人被确定为对照组。采用SPSS 18软件进行统计分析。p值< 0.05为差异有统计学意义。结果:共对139例乳糜泻患者和146例正常儿童进行了研究。乳糜泻患者平均年龄9.1岁,标准差3.4岁。64%的乳糜泻患者是女孩,36%是男孩。而在对照组中,男孩和女孩的这一比例分别为54.4%和48.6%。乳糜泻患者组最常见的HLA为HLA DQ2和8,对照组最常见的HLA为HLA dq8和5。发育不良是乳糜泻患者最常见的症状,共有60名儿童患有乳糜泻。98.6%的患者总IgA滴度正常,93.5%的患者TTG IgA滴度阳性。与乳糜泻合并最常见的疾病是糖尿病,患病率为30例(66.7%)。结论:本研究显示,乳糜泻患者HLA DQ2和8在正常人群中的患病率分别为72.6%和53%。
{"title":"Prevalence of HLA DQ 2, 8 in children with celiac disease.","authors":"Seyed Mohsen Dehghani,&nbsp;Naqi Dara,&nbsp;Behrooz Gharesifar,&nbsp;Iraj Shahramian,&nbsp;Fatemeh Dalili,&nbsp;Morteza Salarzaei","doi":"10.3233/HAB-200437","DOIUrl":"https://doi.org/10.3233/HAB-200437","url":null,"abstract":"<p><strong>Objective: </strong>Celiac disease is a chronic disease that affect small bowel by making its villi become atrophic. Various environmental and genetic factors have been identify as inducing factors for celiac disease. Most of the patients has one of the HLA DQ forms. Although the prevalence of these genes are variable in different areas of the world, we do not have a comprehensive information about this issue in our region. Thus the aim of present study is to investigate the prevalence of HLA DQ typing of patients who visited Emam Reza Gastroenterology clinic of Shiraz(IRAN).</p><p><strong>Methods: </strong>In this case-control study all under 18 years old children who were diagnosed with celiac disease and have visited Emam Reza gastroenterology clinic were investigated. The diagnosis of celiac disease was made by history, physical exam, serologic test, and histopathology of duodenal biopsy. Blood sample was taken and HLA typing performed using PCR method at Motahari clinic cytology laboratory. Also those people who neither them self nor their first degree relatives were not case of celiac disease and underwent HLA typing for other reason were identified as control group. The statistical analysis was done using SPSS 18 software. The p value < 0.05 was identified as statistically significant.</p><p><strong>Results: </strong>A total of 139 patients with celiac disease and 146 normal children were studied. The mean age of the patient with celiac disease were 9.1 years old with standard deviation of 3.4 years old. 64% of the celiac patients were girls and 36% were boys. While this proportion was 54.4% for boy and 48.6% for girls in control group. The most common HLA in celiac patients group were HLA DQ2 and 8 but the most common ones in control group were HLA DQ 8 and 5. Failure to Thrive were the most common signs of the celiac patients with a prevalence of 60 children. Total IgA titer were normal in 98.6% of the patients and TTG IgA titer were positive in 93.5% of the patients. The most common co existing disease with the celiac disease were diabetes with a prevalence of 30 children (66.7%).</p><p><strong>Conclusion: </strong>present study reveals that the prevalence of the HLA DQ2 and 8 among patients with celiac disease is 72.6% and 53% in our normal population.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"123-128"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200437","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25318435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immunogenicity of biologics used in the treatment of inflammatory bowel disease. 用于治疗炎性肠病的生物制剂的免疫原性。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210449
Mariam Bqain, Alex Efimov, David Baker, Angray S Kang

Purpose of the review: Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary cause of immunotherapy failure in IBD patients. The benefits of shifting from the "standard" empirical dose escalation approach to therapeutic drug monitoring with anti-TNFα therapy is explored.

Recent findings: The American Gastroenterology Association and British Society of Gastroenterology both currently recommend the use of reactive therapeutic drug monitoring to guide treatment, following loss of response in inflammatory bowel disease patients with active disease. However, further research is required to prove the efficacy of a proactive therapeutic drug monitoring approach alone in remitted IBD patients.

Summary: A combination of personalised monitoring approach for anti-drug antibodies and therapeutic drug monitoring could provide beneficial treatment outcome for people with inflammatory bowel disease by predicting drug failure prior to clinical symptoms and allowing timely switching to an alternative drug.

回顾的目的:在这里,我们批判性地评价炎症性肠病患者免疫治疗失败的文献。特别是抗药物抗体的产生,以及随后的反应丧失是IBD患者免疫治疗失败的主要原因。从“标准”经验剂量递增方法转向抗tnf - α治疗药物监测的好处进行了探讨。最近的发现:美国胃肠病学协会和英国胃肠病学协会目前都推荐使用反应性治疗药物监测来指导治疗炎症性肠病患者的活动性疾病。然而,需要进一步的研究来证明主动治疗药物监测方法在缓解的IBD患者中的有效性。摘要:抗药物抗体的个性化监测方法和治疗性药物监测相结合,可以在临床症状出现之前预测药物失效,并允许及时切换到替代药物,从而为炎症性肠病患者提供有益的治疗结果。
{"title":"Immunogenicity of biologics used in the treatment of inflammatory bowel disease.","authors":"Mariam Bqain,&nbsp;Alex Efimov,&nbsp;David Baker,&nbsp;Angray S Kang","doi":"10.3233/HAB-210449","DOIUrl":"https://doi.org/10.3233/HAB-210449","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary cause of immunotherapy failure in IBD patients. The benefits of shifting from the \"standard\" empirical dose escalation approach to therapeutic drug monitoring with anti-TNFα therapy is explored.</p><p><strong>Recent findings: </strong>The American Gastroenterology Association and British Society of Gastroenterology both currently recommend the use of reactive therapeutic drug monitoring to guide treatment, following loss of response in inflammatory bowel disease patients with active disease. However, further research is required to prove the efficacy of a proactive therapeutic drug monitoring approach alone in remitted IBD patients.</p><p><strong>Summary: </strong>A combination of personalised monitoring approach for anti-drug antibodies and therapeutic drug monitoring could provide beneficial treatment outcome for people with inflammatory bowel disease by predicting drug failure prior to clinical symptoms and allowing timely switching to an alternative drug.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 4","pages":"225-235"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210449","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39251787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. SARS-CoV-2 IgG对核衣壳和刺突抗原检测的比较评价。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210440
Mitra Rezaei, Mohammadhadi Sadeghi, Alireza Korourian, Payam Tabarsi, Mihan Porabdollah, Elham Askari, Esmaeil Mortaz, Shima Mahmoudi, Majid Marjani, Ali Akbar Velayati

Background: There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.

Objective: The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.

Methods: The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.

Results: Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).

Conclusion: Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.

背景:比较抗刺突(S)抗体和抗核蛋白(N)抗体对SARS-CoV-2反应的研究很少。目的:评价病毒S抗原和N抗原IgG抗体的产生及其与发病时间和严重程度的相关性。方法:采用ELISA技术检测72例SARS-CoV-2实时逆转录聚合酶链反应阳性患者血清中SARS-CoV-2 S、N抗原IgG抗体。比较不同抗体反应,并评价与发病时间和严重程度的相关性。结果:72例患者中48例(67%)检测出抗sars - cov -2抗体阳性,24例(33%)未检测到抗体。N抗体和S抗体的抗体水平比较表明,它们之间的相关性很好(r= 0.81;P < 0.001)。而在症状出现后的前7天,抗- s - cov -2 IgG和抗- n - cov -2 IgG的敏感性分别为30%和60% (r= 0.53;P= 0.111),但在症状出现后1周以上分别增加到73%和68% (r= 0.89, P= 0.111)。IgG阳性组CD8+ T细胞百分比较IgG阴性组降低(抗n IgG组为26±14比58±32,p= 0.066;抗s IgG组为28±15比60±45,p= 0.004)。结论:近三分之一的新冠肺炎确诊患者血清学结果为阴性。使用抗s - SARS-COV-2 IgG试剂盒与抗n - SARS-COV-2 IgG相比,在症状出现后(不到1周)的早期时间点的阳性率较低;因此,临床医生应谨慎解释血清学阴性结果,特别是抗SARS-CoV-2 IgG。
{"title":"Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.","authors":"Mitra Rezaei,&nbsp;Mohammadhadi Sadeghi,&nbsp;Alireza Korourian,&nbsp;Payam Tabarsi,&nbsp;Mihan Porabdollah,&nbsp;Elham Askari,&nbsp;Esmaeil Mortaz,&nbsp;Shima Mahmoudi,&nbsp;Majid Marjani,&nbsp;Ali Akbar Velayati","doi":"10.3233/HAB-210440","DOIUrl":"https://doi.org/10.3233/HAB-210440","url":null,"abstract":"<p><strong>Background: </strong>There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.</p><p><strong>Methods: </strong>The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.</p><p><strong>Results: </strong>Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).</p><p><strong>Conclusion: </strong>Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"109-113"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25481445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19. COVID-19的全球公共卫生意义、社区卫生保健观念、治疗、预防和控制方法。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200422
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.

Methods: For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.

Results: The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.

Conclusion: The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.

背景:2019年新型冠状病毒病(COVID-19)已被证明是有史以来最严重的呼吸道疾病疫情之一。此外,自2020年3月以来,世界卫生组织(世卫组织)将2019冠状病毒病疫情视为全球卫生关注的突发公共卫生事件,全球范围内的发病率和死亡率显著上升。本综述的目的是描述和回顾全球公共卫生意义以及社区和医疗保健对特征、治疗、预防和控制方法的认识,以减缓疫情的传播。方法:本综述通过medRxiv、pubmed、medline和Google scholar等在线数据库进行文献检索。检索关键词为“COVID-19”、“2019 novel coronavirus”、“2019- ncov”、“novel coronavirus”和“Pneumonia”。纳入了2020年1月1日至5月6日期间由美国疾病控制中心(CDC)和世卫组织在线发表的英文科学论文进行分析。结果:本综述结果表明,COVID-19是一个严重的全球性公共卫生问题。它对慢性疾病患者、老年人和孕妇的影响更为严重。这种疾病从一个国家迅速传播到世界各国。总共有212个国家强调了基本公共卫生和应急服务的薄弱状况。研究人员解决了包括卫生专业人员在内的社区对COVID-19缺乏认识的问题。根据病毒的大流行性质、发病情况和疾病暴发的总体特征对医疗保健环境进行了分析。微生物学家还评估了COVID-19的每日累积指数。在治疗方面,磷酸氯喹和草药被证明有希望作为减缓COVID-19传播的支持性治疗,再加上隔离和检疫技术。结论:本文综述表明,新型冠状病毒病具有较高的发病率和死亡率,具有较高的全球公共卫生意义。尽管采取了不同的预防和控制方法,但目前还没有专门有效的疫苗或治疗方法,包括卫生专业人员在内的社会对COVID-19的认知度较低。因此,有必要提高认识,同时进一步开展研究,寻找有效的疫苗和治疗方法。
{"title":"Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200422","DOIUrl":"https://doi.org/10.3233/HAB-200422","url":null,"abstract":"<p><strong>Background: </strong>The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.</p><p><strong>Methods: </strong>For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.</p><p><strong>Results: </strong>The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.</p><p><strong>Conclusion: </strong>The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Global burden of COVID-19: Situational analyis and review. COVID-19全球负担:情况分析和审查。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200420
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.

Objective: This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.

Methods: The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.

Results: The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.

Conclusion: The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.

背景:2019年新型冠状病毒病(COVID-19)是全球主要的公共卫生负担。由于这种疾病,全球社会的发病率和死亡率不时急剧增加。目的:本情景分析旨在分析COVID-19的流行和发病率,为科学界、利益相关者、卫生保健从业人员和决策者提供明确的疫情信息。方法:通过检索medRxiv、Google scholar和PubMed等官方知名的关键在线数据库进行文献检索。在线数据库包含了从12月31日至2020年4月3日在线发表的大多数英语生物医学期刊和科学论文的档案。文献检索后,文章由两位审稿人独立筛选。结果:全球各大洲累计确诊病例1202320例,其中欧洲(51.2%)、北美(27.7%)、亚洲(17.9%)、南美(1.96%),非洲和澳大利亚确诊病例较少,分别占0.8%和0.5%。但是,本次审查结果显示,在审查期间,亚洲新增确诊病例109555例,非洲新增确诊病例8658例,北美新增确诊病例332866例,南美新增确诊病例20269例,欧洲新增确诊病例568894例,澳大利亚新增确诊病例5051例,除南极洲外,全球新增确诊病例1045403例。总体结果表明,在审查期间记录了1 098 762例病例和59 172例死亡。结果,66个国家的COVID-19死亡人数为零。结论:综述结论:COVID-19;SARS-CoV-2是世界上主要的公共卫生负担,全球发病率和死亡率不时急剧上升。所有部门之间的密切合作,并制定有效的预防和控制战略,包括呆在家里、保持社交/身体距离、隔离、检测疑似患者、隔离和管理确诊病例。因此,各国应尽快在社区层面实施五大疫情防控规划。
{"title":"Global burden of COVID-19: Situational analyis and review.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200420","DOIUrl":"https://doi.org/10.3233/HAB-200420","url":null,"abstract":"<p><strong>Background: </strong>The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.</p><p><strong>Objective: </strong>This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.</p><p><strong>Methods: </strong>The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.</p><p><strong>Results: </strong>The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.</p><p><strong>Conclusion: </strong>The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"139-148"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38269910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
The effect of T helper (Th)/T cytotoxic (Tc) ratio on disease severity in type A hemophilia patients. 辅助T (Th)/T细胞毒(Tc)比值对A型血友病患者病情严重程度的影响
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200434
Hossein Ali Khazaei, Majid Naderi, Ghasem Miri Aliabad, Seyed Mohammad Nasiraldin Tabatabaei, Ali Alidadi, Nezar Ali Moulaei, Mohammad Safdari, Hedayatollah Nahvi, Nader Cohan, Javid Dehghan, Ahmad Mehraban, Arman Jalili, Amin Khazaei, Ehsan Khazaei, Bahman Khazaei, Behnam Khazaei, Nima Rezaei, Morteza Salarzaie, Gholamreza Soleimani

Background and objectives: The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.

Material and method: Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.

Results: Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.

Conclusion: The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.

背景与目的:本研究的目的是探讨儿童A型血友病患者T辅助(Th)与T细胞毒性(Tc)的比值,并评价该比值与疾病严重程度的相关性。材料与方法:采集EDTA抗凝全血2 ml。使用双CD4和CD8试剂盒,通过FACS分析淋巴细胞计数的免疫表型。计算CD4和CD8淋巴细胞绝对数目/ml的平均值±SD,并采用统计学方法评价CD4/CD8比值。结果:80例A型血友病患者中,男性66例,占82.5%。平均年龄15±3.51岁。其中轻症12例(15%),重症68例(85%)。CD4 /CD8比值在0.45 ~ 1.44之间,平均值为1.79±0.78。该比例与疾病严重程度的相关系数为0.019。结论:A型血友病患者CD4/CD8比值与病情严重程度相关,但与性别无关。
{"title":"The effect of T helper (Th)/T cytotoxic (Tc) ratio on disease severity in type A hemophilia patients.","authors":"Hossein Ali Khazaei,&nbsp;Majid Naderi,&nbsp;Ghasem Miri Aliabad,&nbsp;Seyed Mohammad Nasiraldin Tabatabaei,&nbsp;Ali Alidadi,&nbsp;Nezar Ali Moulaei,&nbsp;Mohammad Safdari,&nbsp;Hedayatollah Nahvi,&nbsp;Nader Cohan,&nbsp;Javid Dehghan,&nbsp;Ahmad Mehraban,&nbsp;Arman Jalili,&nbsp;Amin Khazaei,&nbsp;Ehsan Khazaei,&nbsp;Bahman Khazaei,&nbsp;Behnam Khazaei,&nbsp;Nima Rezaei,&nbsp;Morteza Salarzaie,&nbsp;Gholamreza Soleimani","doi":"10.3233/HAB-200434","DOIUrl":"https://doi.org/10.3233/HAB-200434","url":null,"abstract":"<p><strong>Background and objectives: </strong>The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.</p><p><strong>Material and method: </strong>Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.</p><p><strong>Results: </strong>Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.</p><p><strong>Conclusion: </strong>The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"95-99"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200434","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38764909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. 抗神经粘附分子-1抗原干扰成纤维细胞生长因子受体-1结合的人“噬菌体展示”衍生抗体的分离和初步鉴定。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200431
Michela Flego, Gianni Colotti, Alessandro Ascione, Maria Luisa Dupuis, Eleonora Petrucci, Roberta Riccioni, Mauro Andreotti, Carla Raggi, Alessandra Boe, Stefano Barca, Mara Gellini, Stefano Vella, Alessandra Mallano

Background: The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.

Objective: Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.

Methods: The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.

Results: It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.

Conclusions: According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.

背景:NCAM或CD56抗原是一种细胞表面糖蛋白,属于免疫球蛋白超家族,参与细胞-细胞和细胞-基质的粘附。NCAM在许多肿瘤类型中也过表达,被认为是一种肿瘤相关抗原,尽管其在肿瘤进展和转移中的作用和生物学机制尚未阐明。特别是,NCAM蛋白与成纤维细胞生长因子受体-1之间的相互作用在转移和侵袭中的作用,特别是在卵巢癌的进展中,已经有很好的文献记载。目的:本文描述了一种新型人抗ncam单链片段可变抗体的分离和初步鉴定,该抗体能够特异性结合表达ncam的细胞,包括上皮性卵巢癌细胞。方法:采用噬菌体展示筛选法分离该抗体,采用ELISA、FACS和SPR实验对其进行鉴定。通过划痕试验分析了EOC运移过程中的干扰。结果:它结合位于两个纤维连接蛋白样结构域的膜近端区域的部分线性表位,解离常数为3.43 × 10-8 m。有趣的是,它被证明可以干扰NCAM-FGFR1的结合,并部分减少EOC细胞的迁移。结论:据我们所知,这是第一个能够干扰这种新的个体化癌症机制的完全人类抗体。
{"title":"Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.","authors":"Michela Flego,&nbsp;Gianni Colotti,&nbsp;Alessandro Ascione,&nbsp;Maria Luisa Dupuis,&nbsp;Eleonora Petrucci,&nbsp;Roberta Riccioni,&nbsp;Mauro Andreotti,&nbsp;Carla Raggi,&nbsp;Alessandra Boe,&nbsp;Stefano Barca,&nbsp;Mara Gellini,&nbsp;Stefano Vella,&nbsp;Alessandra Mallano","doi":"10.3233/HAB-200431","DOIUrl":"https://doi.org/10.3233/HAB-200431","url":null,"abstract":"<p><strong>Background: </strong>The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.</p><p><strong>Objective: </strong>Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.</p><p><strong>Methods: </strong>The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.</p><p><strong>Results: </strong>It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.</p><p><strong>Conclusions: </strong>According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"63-84"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38584014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Altered expression of STAT genes in periodontitis. 牙周炎中STAT基因表达的改变。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210444
Leila Gholami, Abolfazl Movafagh, Elham Badrlou, Naghme Nazer, Mohsen Yari, Ghasem Sadeghi, Sara Mirzajani, Mahdi Shadnoush, Arezou Sayad, Soudeh Ghafouri-Fard

Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.

信号换能器和转录激活器(Signal Transducer and Activator of Transcription, STAT)通路在功能上位于Janus激酶蛋白的下游,可以整合多种通路的信号,从而调节免疫应答的多个方面。虽然STAT蛋白在几种炎症的发病机制中的作用已经得到证实,但它们在牙周炎发展中的作用却很少得到评价。因此,我们评估了受影响个体的牙周组织和循环中STAT转录本的水平,并与相应的对照进行了比较。STAT1在患者组织样本中的表达明显低于对照组(RME = 0.15, SE = 0.99, P值= 0.01)。STAT3在牙周炎组织中的表达低于对照组(RME = 0.20, SE = 0.95, P值= 0.02)。STAT6在牙周炎总组织中的表达高于对照组(RME = 0.5.38, SE = 0.74, P值< 0.001)。其他STAT基因在病例和对照组织中的表达在统计学上相似。此外,所有STAT基因的血液水平在患者和对照组之间具有统计学上的相似。相关分析表明,个体STAT基因的组织水平之间以及血液水平之间存在显著相关性。然而,组织和血液中每个STAT基因的水平并不相关。目前的研究增强了某些STAT基因在这种免疫相关疾病发展中的作用,并保证了功能分析来阐明其机制。
{"title":"Altered expression of STAT genes in periodontitis.","authors":"Leila Gholami,&nbsp;Abolfazl Movafagh,&nbsp;Elham Badrlou,&nbsp;Naghme Nazer,&nbsp;Mohsen Yari,&nbsp;Ghasem Sadeghi,&nbsp;Sara Mirzajani,&nbsp;Mahdi Shadnoush,&nbsp;Arezou Sayad,&nbsp;Soudeh Ghafouri-Fard","doi":"10.3233/HAB-210444","DOIUrl":"https://doi.org/10.3233/HAB-210444","url":null,"abstract":"<p><p>Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 3","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39050903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The level of risk, effects response to potential health emergencies, prevention and control method of COVID-19: A systematic review. 2019冠状病毒病风险水平、潜在突发卫生事件应对效果、防控方法综述
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200421
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.

Method: A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.

背景:COVID-19是目前世界上主要的公共卫生负担,全球范围内因COVID-19引起的疾病和死亡人数不时迅速增加。然而,缺乏关于该疾病的风险程度、影响、预防和控制方法的组织良好的信息。因此,本研究的目的是在全球范围内确定和审查已公布的COVID-19风险水平、对潜在卫生突发事件的影响响应以及预防和控制方法。方法:通过检索medRxiv、Google scholar、PubMed、MEDLINE、EMBASE和Cochrane Library等在线数据库,并辅以手工检索会议,对文献进行系统评价。在线数据库包含大多数英文生物医学期刊的档案。疾病控制中心和世界卫生组织在网上发表的科学论文也被纳入了这项分析。纳入了2019年12月1日至2020年4月13日的科学出版物。“COVID-19”、“2019新型冠状病毒”、“2019- ncov”、“新型冠状病毒”和“肺炎”关键搜索词被用于本综述。
{"title":"The level of risk, effects response to potential health emergencies, prevention and control method of COVID-19: A systematic review.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200421","DOIUrl":"https://doi.org/10.3233/HAB-200421","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.</p><p><strong>Method: </strong>A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"149-169"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Antibodies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1